Kayseri yöresinde en fazla invaziv hastalık etkeni olan pnömokok serogrupları

Bu çalışmada, bölgemizde İnvaziv hastalık etkeni olarak izole edilen pnömokoklardaki serogruplarla, polisakkarid ve konjuge aşıların içerdiği serogrupların karşılaştırılması amaçlanmıştır. Ocak 1998-Ocak 2000 tarihleri arasında 31 'i beyin omurilik sıvısı (BOS), 28'i kan ve 10'u plevral maiden izole edilen 69 Streptococcus pneumonias susu çalışmaya alınmıştır. Serotiplendirme Pneumotest (Statens Seruminstitute, Danimarka) ile yapılmıştır. Altı (%8) susun serogrubu belirlenemezken, kalan 63 susun sırasıyla serogrup 19, 1,6, 23, 3, 15, 14 ve 7'ye ait olduğu bulunmuştur. Aşılarla yapılan karşılaştırma sonrasında 23-valanlı polisakkarid aşı ile 7-valanlı, 9-valanlı ve l l-valanlı konjuge aşıların sırasıyla suşların %91, %68, %8I ve %87'sini kapsadığı belirlenmiştir. Bu çalışma, bazı serogrupları içermemesine rağmen bütün pnömokok aşıların yöremizdeki İnvaziv pnömokok infeksiyonlannın çoğunu önlemede yeterli olacağını göstermektedir.

Kaynakça

1. Musher DM. Streptococcus pneumoniae. in: Mandell GL, Douglas RG, Bennett JE, Dolin R (eds). Principles and Practice of Infectious Diseases. 4^ ed. New York: Churchill Livingstone Inc, 1995:1811-26. 2. Caputo GM, Appelbaum PC, Liu HH. Infections due to penicillinresistant pneumococci: Clinical, epidemiologic and microbiologic features. Arch Intern Med 1993; 153:1301-10. 3. Janoff EN, Rubins JB. Invasive pneumococcal disease in the immunocompromised host. In: Tomasz A (ed). Streptococcus pneumoniae: Molecular Biology and Mechanisms of Disease. Larchmont: Marry Ann Liebert Inc, 2000:321-41. 4. Redd SC, Rutherford GW 3rd, Sande MA, et al. The role of immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis 1990;162:1012-7. 5. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 1995;33:2759-62. 6. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part 1. Clin Infect Dis 2000;30:100-21. 7. Böken DJ, Chartrand SA, Moland ES, Goering RV. Colonization with penicillin-nonsusceptible Streptococcus pneumoniae in urban and rural child-care centers. Pediatr Infect Dis J 1996; 15:667-72. 8. Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997;278:1333-9. 9. Siber GR. Pneumococcal disease: Prospects for a new generation of vaccines. Science 1994;265:1385-7. 10. Klein DL, Eskola J. Development and testing of Streptococcus pneumoniae conjugate vaccines. Clin Microbiol Infect 1999;5(Suppl 4): 17-28. 11. Pratt Rippin K, Pezzlo M. Identification of gram-positive bacteria. In: Isenberg HD (ed). Clinical Microbiology Procedures Handbook (Vol: 1). Washington DC: ASM Press,1992:19-20. 12. Block SI, Harrison JA, Hedrick RD, et al. Penicillin-resistant Streptococcus pneumoniae in acute otitis media: Risk factors, susceptibility patterns and antimicrobial management. Pediatr Infect Dis J 1995; 14:751-9. 13. Scott JAG, Hall AJ, Dagan R, et al. Serogroup-specific epidemiology of Streptococcus pneumoniae: Associations with age, sex, and geography in 7.000 episodes of invasive disease. Clin Infect Dis 1996;22:973-81. 14. Çavuşoglu C. Pnömokoklarda antibiyotik direnci. Uzmanlık Tezi. Bornova, İzmir, 1996:22. 15. Kocagöz S, Gür D, Ünal S. Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae isolates in a Turkish hospital. 8^ Europian Congress of Clinical Microbiology and Infectious Disease. Poster no:1175, May 25-28, 1997, Lausanne, Switzerland. Clin Microbiol Infect 1997;3(Suppl 2):289-90. 16. Kanra G, Özalp M, Gür D. Distribution of serotypes and antimicrobial resistance of Streptococcus pneumoniae in a children's hospital. 8tn International Congress on Infectious Disease. Poster no: 57. 017, May 15-18, 1998,Boston, USA. 17. Kouppari G, Zaphiropoulou A, Tsolia M, et al. Serotyping and antibiotic resistance of Streptococcus pneumoniae isolated from pediatric infections in central Greece.Clin Microbiol Infect 1998;4:695-700. 18. Fenoll A, Jado I, Vicioso D, et al. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: Update (1990 to 1996). J Clin Microbiol 1998;36:3447-54. 19. Inostroza J, Trucco O, Prado V, et al. Capsular serotype and resistance of Streptococcus pneumoniae isolates in two Chilian cities. Clin Diagn Lab Immunol 1998;5:176-80. 20. Mufson M. Streptococcus pneumoniae. In: Mandell GL Douglas RG, Bennett JE (eds). Principles and Practice of Infectious Diseases. 3rd ed. New York: Churchill Livingstone Inc, 1990:1539-50. 21. Steinhoff MC, Edwards K, Keyserling H, et al. A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: Effect of polysaccharide size and linkage characteristics. Pediatr Infect Dis J 1994;13:368-72. 22. Klein DL. Pneumococcal disease and the role of conjugate vaccines. In: Tomasz A (ed). Streptococcus pneumoniae: Molecular Biology and Mechanisms of Disease. 1st ed. Larchmont: Mary Ann Liebert Inc,2000:467-77. 23. Buttler JC. Epidemiology of pneumococcal serotypes and conjugate vaccine formulations. In: Tomasz A (ed).Streptococcus pneumoniae: Molecular Biology and Mechanisms of Disease. 1st ed. Larchmont: Mary Ann Liebert Inc, 2000:479-84.

Kaynak Göster

Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi
  • ISSN: 1300-932X
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1996
  • Yayıncı: Yeliz İşitmir

16.2b7.9b